Orphazyme Annual Report 2017 Presentation

Orphazyme A/S
Investor news                                                                                                                                     
No. 05/2018

Copenhagen, March 12, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2017. The presentation will be followed by a Q&A session.

The call will be held on: Thursday, March 15, 2018 at 11.00 AM CET.

Dial-in details:

• Denmark: +45 35 15 80 49
• United Kingdom: +44 (0)330 336 9105
• United States: +1 646 828 8156

Event Title: Orphazyme Annual Report 2017
Confirmation code: 7829588

The presentation will also be available via webcast: https://edge.media-server.com/m6/p/gdifg3gn

After the call, the presentation will be available via the above link or by using the following dial-in details.

About Orphazyme A/S
Orphazyme is a Danish biopharmaceutical company focused on the development of treatments for patients living with life-threatening or debilitating rare diseases. Our research is concentrated on the cell-protective properties of the body’s own rescue system for diseases caused by misfolded proteins or lysosomal dysfunction. The company’s lead candidate, arimoclomol, is in development for four severe orphan diseases; two muscle-wasting diseases, sporadic Inclusion Body Myositis (sIBM) and Amyotrophic Lateral Sclerosis (ALS), and two lysosomal storage diseases, Niemann-Pick disease Type C (NPC) and Gaucher disease. We are listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit?www.orphazyme.com. 

05-2018 Orphazyme Annual Report 2017 Presentation